Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXI phase 2/3 trial of guselkumab in moderately to severely active Crohn's disease
MOH_2018-11-08_002501Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (8 arms), sponsored by Janssen Pharmaceutical. Started Aug 2018; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-11-08_002501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-08_002501.